Medtronic Launches the Entrust Delivery System in the United States

August 5, 2015—Medtronic plc announced the United States launch of its Entrust delivery system, which enables placement of the company's EverFlex self-expanding peripheral stent in the treatment of stenotic regions of the superficial femoral and proximal popliteal arteries. The EverFlex stent has been proven clinically safe and effective in treating long, complex, and highly calcified lesions, noted the company.

According to Medtronic, the 5-F triaxial delivery system provides control and precision with a low profile and the ease of a one-handed device. Other features include 0.035-inch guidewire compatibility, longer catheter lengths, and a broad stent matrix. 

George Meier, MD, commented in the company’s press release, “The Entrust delivery system allows me to confidently deliver the EverFlex stent with control and ease, ensuring precise placement of the stent even in difficult, complex, or hard-to-reach lesions." Dr. Meier is Chief of Vascular Surgery at the University of Cincinnati Medical Center in Cincinnati, Ohio.

Luke Marone, MD, of The University of Pittsburgh Medical Center (UPMC) hospitals, added, “The Entrust delivery system is a great example of how industry and physicians can partner to deliver game-changing technology. The low-profile, long catheter option, and one-handed, triaxial delivery system put the Entrust delivery system in a class of its own when it comes to peripheral vascular stents.” Dr. Marone is Chief of Cardiovascular Surgery at UPMC Passavant Hospital and Director of Peripheral Intervention, UPMC Heart and Vascular Institute in Pittsburgh, Pennsylvania.